Adaptive Phage Therapeutics (APT)

BioMX is a biotechnology company based in Gaithersburg, Maryland, USA, that is developing natural and engineered phage therapies to eradicate harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. The company's technological platform, originating from leading scientists at the Weizmann Institute of Science and MIT, enables the discovery and development of customized phage compositions to target specific bacterial targets.